Allogene Therapeutics announced that it has entered into a lease agreement to develop a 118,000 square foot cell therapy manufacturing facility in Newark, California. The new manufacturing facility is being designed to provide GMP manufacturing for clinical supply and commercial product upon potential regulatory approval. Allogene currently manufactures its clinical trial supply through a contract manufacturing organization, which continues to remain a component of the company’s long-term manufacturing strategy.
https://thefly.com/landingPageNews.php?id=2866925
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.